# Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Study · id `cardio:ct-nct06953726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06953726](<https://clinicaltrials.gov/study/NCT06953726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06953726

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.

## Technical summary

Registry record NCT06953726. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2032-10-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 10000 participants (planned count; ClinicalTrials.gov record NCT06953726, source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)
- Started: 2026-06-01 (actual) (ClinicalTrials.gov record NCT06953726, source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)
- Primary completion: 2032-10-04 (anticipated) (ClinicalTrials.gov record NCT06953726, source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)
- Completion: 2033-10-03 (anticipated) (ClinicalTrials.gov record NCT06953726, source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06953726, source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06953726-2026-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
- Acronym: VALIANT-AF-T
- Condition: Atrial Fibrillation
- Intervention (Drug): Apixaban
- Intervention (Drug): Rivaroxaban
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED
- Collaborator: Food and Drug Administration (FDA)
- Collaborator class: FED

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: bec9f46c18d37e20f912348f15bb1060460535d5bb5cc47328732baebc767e2a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
